ESSITY-B Stock Analysis: Essity (publ) | ST
Household & Personal Products | ST, Sweden | Market Cap: 186.398m SEK | 12M Return: 8.5% | SE0009922164 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 353M
EPS Trend: 30.2%
Qual. Beats: 1
Rev. Trend: -89.7%
Qual. Beats: 0
Warnings
Tailwinds
No distinct edge detected
Seasonality 9.3 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Essity AB (publ) is a Swedish hygiene and health company founded in 1849 and headquartered in Stockholm. It operates globally across Europe, the Americas, and Asia through three reporting segments: Health & Medical, Consumer Goods, and Professional Hygiene, selling products under a broad portfolio of brands including TENA, Tork, Libresse, Zewa, and JOBST.
The business model spans both consumer-facing retail and business-to-business channels. The Consumer Goods segment sells feminine care, baby care, and household tissue products through retail and e-commerce, while the Professional Hygiene segment supplies washroom, cleaning, and wiping solutions under the Tork brand directly to workplaces, healthcare facilities, hospitality venues, and public institutions. The Health & Medical segment distributes incontinence, wound care, compression therapy, and orthopedic products through pharmacies, hospitals, and medical device channels.
Essity is classified within the Consumer Staples sector and the Personal Care Products sub-industry, reflecting the non-cyclical nature of its core categories such as tissue, incontinence care, and feminine hygiene, which tend to exhibit relatively stable demand across economic cycles.
- Pulp and raw material costs pressure gross margins
- Professional Hygiene revenue recovers as offices and travel resume
- TENA incontinence sales grow on aging European demographics
| Net Income: 11.1b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA 2.65 > 1.0 |
| NWC/Revenue: 4.77% < 20% (prev 8.62%; Δ -3.84% < -1%) |
| CFO/TA 0.10 > 3% & CFO 18.7b > Net Income 11.1b |
| Net Debt (36.6b) to EBITDA (24.4b): 1.50 < 3 |
| Current Ratio: 1.13 > 1.5 & < 3 |
| Outstanding Shares: last quarter (676.7m) vs 12m ago -1.56% < -2% |
| Gross Margin: 32.40% > 18% (prev 32.61%; Δ -0.21% > 0.5%) |
| Asset Turnover: 78.83% > 50% (prev 84.48%; Δ -5.64% > 0%) |
| Interest Coverage Ratio: 14.05 > 6 (EBIT TTM 17.0b / Interest Expense TTM 1.21b) |
| A: 0.04 (Total Current Assets 58.2b - Total Current Liabilities 51.5b) / Total Assets 185b |
| B: 0.45 (Retained Earnings 82.8b / Total Assets 185b) |
| C: 0.10 (EBIT TTM 17.0b / Avg Total Assets 176b) |
| D: 1.11 (Book Value of Equity 97.2b / Total Liabilities 87.4b) |
| Altman-Z'' = 3.51 = A |
| DSRI: 1.15 (Receivables 30.9b/27.4b, Revenue 139b/142b) |
| GMI: 1.01 (GM 32.61% / 32.40%) |
| AQI: 1.04 (AQ_t 0.39 / AQ_t-1 0.38) |
| SGI: 0.98 (Revenue 139b / 142b) |
| TATA: -0.04 (NI 11.1b - CFO 18.7b) / TA 185b) |
| Beneish M = -2.89 (Cap -4..+1) = A |
As of October 29, 2026, the stock is trading at SEK 274.50 with a total of 1,032,016 shares traded. Over the past week, the price has changed by -0.72%, over one month by +5.94%, over three months by -2.17% and over the past year by +8.45%.
Current recommended Stop Loss: 263.90 (which is 3.9% or 2.3 ATR below the current price).
Essity (publ) has no consensus analysts rating.
P/E Trailing = 16.9278
P/E Forward = 13.21
P/S = 1.3411
P/B = 2.1043
P/EG = 2.7537
Revenue TTM = 139b SEK
EBIT TTM = 17.0b SEK
EBITDA TTM = 24.4b SEK
Long Term Debt = 27.7b SEK (from longTermDebt, last fiscal year)
Short Term Debt = 13.9b SEK (from shortTermDebt, last quarter)
Debt = 43.2b SEK (from shortLongTermDebtTotal, last quarter) + Leases 3.96b
Net Debt = 36.6b SEK (calculated: Debt 43.2b - CCE 6.56b)
Enterprise Value = 223b SEK (186b + Debt 43.2b - CCE 6.56b)
Interest Coverage Ratio = 14.05 (Ebit TTM 17.0b / Interest Expense TTM 1.21b)
EV/FCF = 18.71x (Enterprise Value 223b / FCF TTM 11.9b)
FCF Yield = 5.35% (FCF TTM 11.9b / Enterprise Value 223b)
FCF Margin = 8.58% (FCF TTM 11.9b / Revenue TTM 139b)
Net Margin = 8.00% (Net Income TTM 11.1b / Revenue TTM 139b)
Gross Margin = 32.40% ((Revenue TTM 139b - Cost of Revenue TTM 94.0b) / Revenue TTM)
Gross Margin QoQ = 29.30% (prev 32.65%)
Tobins Q-Ratio = 1.21 (Enterprise Value 223b / Total Assets 185b)
Interest Expense / Debt = 2.80% (Interest Expense 1.21b / Debt 43.2b)
Taxrate = 25.88% (3.90b / 15.1b)
NOPAT = 12.6b (EBIT 17.0b * (1 - 25.88%))
Current Ratio = 1.13 (Total Current Assets 58.2b / Total Current Liabilities 51.5b)
Debt / Equity = 0.44 (Debt 43.2b / totalStockholderEquity, last quarter 97.2b)
Debt / EBITDA = 1.50 (Net Debt 36.6b / EBITDA 24.4b)
Debt / FCF = 3.07 (Net Debt 36.6b / FCF TTM 11.9b)
Total Stockholder Equity = 90.8b (last 4 quarters mean from totalStockholderEquity)
RoA = 6.31% (Net Income 11.1b / Total Assets 185b)
RoE = 12.25% (Net Income TTM 11.1b / Total Stockholder Equity 90.8b)
RoCE = 14.35% (EBIT 17.0b / Capital Employed (Equity 90.8b + L.T.Debt 27.7b))
RoIC = 8.95% (NOPAT 12.6b / Invested Capital 141b)
WACC = 4.59% (E(186b)/V(230b) * Re(5.17%) + D(43.2b)/V(230b) * Rd(2.80%) * (1-Tc(0.26)))
Discount Rate = 5.17% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -99.74 | Cagr: -1.61%
[DCF] Terminal Value 77.97% ; FCFF base≈9.70b ; Y1≈11.1b ; Y5≈16.4b
[DCF] Fair Price = 338.0 (EV 246b - Net Debt 36.6b = Equity 210b / Shares 619.9m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 30.23 | EPS CAGR: 0.79% | SUE: 3.20 | # QB: 1
Revenue Correlation: -89.73 | Revenue CAGR: -5.90% | SUE: -0.08 | # QB: 0
EPS current Quarter (2027-03-31): EPS=4.66 | Chg30d=+1.75% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=18.63 | Chg30d=-0.66% | Revisions=-79% | GrowthEPS=+0.9% | GrowthRev=+1.8%
EPS next Year (2027-12-31): EPS=19.94 | Chg30d=-2.48% | Revisions=-64% | GrowthEPS=+7.1% | GrowthRev=+4.9%
[Analyst] Revisions Ratio: -81% (up=1, down=22)